From the start, the DNA sequencing leader faced pressure to unwind its $8 billion acquisition of the cancer screening developer. As 2023 drew to a close, it has finally agreed.
Roundup: Illumina’s long goodbye to cancer test maker Grail Read More »
Flattening wage growth, declining quit rates and rising payrolls are signs the red-hot labor market is stabilizing. However, the credit agency said recruitment still remains “hyper-competitive.”
Labor conditions stabilizing at nonprofit hospitals: Fitch Read More »
The Securities and Exchange Commission alleges that Laura Tyler Perryman approved the creation of “fake” implantable parts for the company’s PNS device and defrauded investors of $41 million.
SEC charges former Stimwave CEO with $41M fraud scheme Read More »
Enrollment in the Affordable Care Act exchanges could be boosted by extended subsidies and the effects of Medicaid redeterminations.
Over 19M could enroll in ACA plans for 2024, CMS says Read More »
Pressure BioSciences, Inc. today announced the publication of a powerful visionary article in the respected industry trade magazine “Food Technology” published by the Institute of Food Technologists (“IFT”).
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
Bedrock Bioscience is thrilled to announce the publication of a groundbreaking medical study in the esteemed International Journal of Clinical Medicine.
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and Development Authority (BARDA) to implement the first BARDA-supported Phase II platform clinical trial to investigate multiple therapeutic options for the treatment of acute respiratory distress syndrome (ARDS).
Pluristyx, a leading provider of tools, technologies and services for the development of cell therapies, has today announced the closing of a major fundraising round led by BroadOak Capital Partners.
Pluristyx Announces Major New Funding Round to Bolster Expansion Plans Read More »
La migraña, más que un simple dolor de cabeza, es una afección compleja que afecta a millones en todo el mundo. Por eso es importante identificarla y aplicar estrategias efectivas para combatirla y mejorar la calidad de vida. Entendiendo la Migraña: Más Al …
